Description: Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Home Page: www.caratherapeutics.com
400 Atlantic Street
Stamford,
CT
06901
United States
Phone:
203 406 3700
Officers
| Name | Title |
|---|---|
| Mr. Christopher A. Posner | President, CEO & Director |
| Mr. Ryan D. Maynard | Chief Financial Officer |
| Dr. Derek T. Chalmers D.Sc., Ph.D. | Co-Founder & Senior Advisor |
| Mr. Matthew Murphy | Manager of Investor Relations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 18.9886 |
| Price-to-Sales TTM: | 1.278 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 55 |